Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 12—December 2019

High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014–2016

Lijun Li1, Jikui Deng1, Xiang Ma1, Kai Zhou1, Qinghong Meng, Lin Yuan, Wei Shi, Qing Wang, Yue Li, and Kaihu YaoComments to Author 
Author affiliations: Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, Beijing, China (L. Li, Q. Meng, L. Yuan, W. Shi, Q. Wang, Y. Li, K. Yao); Shenzhen Children’s Hospital, Shenzhen, China (J. Deng); Jinan Children’s Hospital, Shandong University, Shandong, China (X. Ma); Nanjing Children’s Hospital, Nanjing Medical University, Nanjing, China

Main Article

Table 2

Antimicrobial susceptibility test results for Bordetella pertussis isolates in study of prevalence of macrolide-resistant B. pertussis and ptxP1 genotype, mainland China, 2014–2016*

Drug No. isolates E‐test, mg/L
Kirby-Bauer disk diffusion
MIC50 MIC90 MIC range Range of inhibition zone, mm Rate of susceptibility, %†
Erythromycin 335 >256 >256 0.032 to >256 668 12.5%
Clindamycin 335 >256 >256 0.25 to >256 NT NT
Amoxicillin 335 0.5 1 0.125 to 2 NT NT
Ampicillin 335 0.25 0.5 0.032 to 1 NT NT
Levofloxacin 335 0.5 1 0.064 to 1 NT NT
Sulfamethoxazole 335 0.064 0.25 0.002 to 0.5 NT NT
Ceftriaxone 335 0.25 0.5 0.064 to 2 NT NT
Amikacin 222 8 8 2 to 32 NT NT
Clarithromycin 83 >256 >256 0.032 to >256 NT NT
Azithromycin 83 >256 >256 0.016 to >256 NT NT
Doxycycline 310 8 8 1 to 16 NT NT
Aztreonam 86 8 32 4 to 32 NT NT

*NT, not tested in this study.
†An inhibition diameter >42 mm suggested that the isolate was susceptible to erythromycin.

Main Article

1These authors contributed equally to this article.

Page created: November 18, 2019
Page updated: November 18, 2019
Page reviewed: November 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.